Trial Profile
A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms HCV RESPOND-2; RESPOND-2
- Sponsors Merck Sharp & Dohme Corp.
- 15 Jun 2019 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database.
- 30 Apr 2013 Results presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases.
- 07 Jul 2012 Additional trial location (United Kingdom) added as reported by European Clinical Trials Database record.